Comfort Letters Ordinarily Are Signed By The Client’s
Comfort Letters Ordinarily Are Signed By The Client’s – EXECUTION VERSION GLOBE LIFE INC. (Delaware Corporation) $50,000,000 2.150% Notes 2030 Underwriting Agreement Dated: August 31, 2020
GLOBE LIFE INC. (Delaware Corporation) $50,000,000 2.150% Notes 2030 Underwriting Agreement August 31, 2020 BofA urities, Inc. Here are several SBancorp Investments, Inc. BofA urities, Inc. One Bryant Park New York, NY 10036 c/o U.S. Bancorp Investments, Inc. 214 N. Tryon Street, 26th Floor Charlotte, North Carolina 28202 As Representatives of the Several Underwriters Named on Schedule A: Hereby Globe Life Inc., a Delaware Corporation (the “Company”), to the Several Underwriters Named on Schedule A (the “Underwriters”). and proposes to sell, not jointly and severally, the Company’s 2.150% Notes due 2030 (the “Notes”) for the respective principal amounts set forth in such Schedule. BofA urities, Inc. and the U.S. Bancorp Investments, Inc. A number of the underwriters (in such capacity, the “Representatives”) have agreed to act as representatives in connection with the offering and sale of the Notes. The Notes are issued pursuant to an indenture dated as of September 24, 2018 (the “Base Indenture”) between the Company and Regions Bank as trustee (“Trustee”). Certain terms of the Notes are established pursuant to a Supplemental Indenture dated August 21, 2020 (the “Supplemental Indenture and, together with the Base Indenture, the “Indenture”). The Notes form a single series and are dated August 21, 2020 as the Base Indenture and one Supplemental Indenture (the “Outstanding”). Notes” issued pursuant to $350,000,000 aggregate principal amount of 2.150% of the Notes due 2030 are fully fungible. Pursuant to a blanket issuer representation letter dated August 18, 2020, as nominee of The Depository Trust Company (“DTC”), in the name of Cede & Co. The Notes are issued in book-entry form (the “DTC” Agreement”), between the Company and DTC. The Company has prepared and filed with the Securities and Exchange Commission (the “Commission”) an “Automated Shelf Registration Statement” pursuant to Rule 405 under the Securities Act of 1933 (“ as defined under Rule 405″) (the “Urities” Act”), notes and notes outstanding under the Uriities Act and the rules and regulations promulgated thereunder. Form S-3 (File No. 333-227501) (the “Eruties Act Regulations”), which is effective upon the filing of an automatic shelf registration statement under Rule 462(e) of the Securities Act Regulations (“Rule 462(e)”). Such registration statement, at any time, as amended by any subsequent effective amendment at such time, shall mean that such registration statement, including the exhibits and any schedules at such time, incorporates or is deemed to be incorporated by reference therein. Time pursuant to Item 12 of Form S-3 under the Uriities Act and
Comfort Letters Ordinarily Are Signed By The Client’s
Documents deemed to be part thereof pursuant to Rule 430B of the Securities Act Regulations (“Rule 430B”) and referred to herein as the “Registration Statement”. Each preliminary prospectus supplement and the base prospectus used in connection with the offering of the Notes, including the documents incorporated or deemed to be incorporated by reference therein in accordance with Item 12 of Form S-3 under the Securities Act immediately prior to the applicable time, as described below), are collectively referred to herein as the “Preliminary Prospectus”. . Upon the execution and delivery of this Agreement (this “Agreement”), the Company will prepare and file a final prospectus supplement relating to the Notes in accordance with the provisions of the Securities Act Regulations (“Rule 424 (“Rule 424(b)”). . The Final Prospectus Supplement and the Base Prospectus, in the form first furnished to the underwriters for use in connection with the offer and sale of the Notes, are documents incorporated or deemed to be incorporated by reference therein in accordance with Item 12 of Form S. 3 as of the applicable time under the Uriities Act, collectively referred to herein as the “Prospectus”. For purposes of this Agreement, all references to the registration statement, any preliminary prospectus or prospectus or any amendment or supplement shall be deemed to include a copy filed with the Commission pursuant to its (or any) electronic data collection, analysis and retrieval system. Successor System)(“EDGAR”). As used in this Agreement: “Applicable Time” means 11:20 A.M. New York City time, on August 31, 2020, or such other time as may be agreed upon by the Company and the Representatives. “ Common Disclosure Package ” means each Issuer’s Common Use Free Writing Prospectus and the most recent Preliminary Prospectus provided to the Underwriters for general distribution to Investors prior to the Applicable Time, taken together. “ Issuer’s Free Writing Prospectus ” means any “issuer’s free writing prospectus” as defined in Rule 433 of the Securities Act Regulations (“Rule 433”), including any “free writing prospectus” (as defined in Rule 405). (i) relates to notes that the company is required to file with the Commission, (ii) is a “road show that is a written communication” within the meaning of rule 433(d)(8)(i), or is not required to be filed with the Commission, or (iii) is required to be filed with the Commission under rule 433(d)(5)( (i) is exempt from filing with the Commission pursuant to subsection (1) because it does not reflect the Notes or its offering description of the final regulations, in the form filed or required to be filed with the Commission in each case or, if filing is not required, in the form retained in the company’s records pursuant to Rule 433(g). “issuer’s general use free writing prospectus” means any issuer’s free writing prospectus intended for general distribution to investors, as specified in Schedule B; “ Issuer’s Limited Use Free Writing Prospectus ” means any Issuer’s Free Writing Prospectus that is not an Issuer’s General Use Free Writing Prospectus. All references to financial statements and schedules in this Agreement and to other information that is “included,” “included” or “stated” (or other references to import) in the registration statement shall be deemed to include any preliminary prospectus or prospectus. All such financial statements and schedules and other information incorporated or deemed to be incorporated by reference in the registration statement, any preliminary prospectus or prospectus, prior to the applicable time; and all references in this Agreement to amendments or supplements to the Registration Statement, any preliminary prospectus or prospectus shall be deemed to include the filing of any document under the Securities Exchange Act of 1934 (the “Exchange Act”), and the Rules and Regulations 2
Llb142 Regulation Of Business Law Notes
Incorporated or deemed incorporated by reference in the registration statement published thereunder (the “Exchange Act Rules”), such preliminary prospectus or prospectus, as may be at or after the applicable time. The Company confirms its agreements with the underwriters as follows: TION 1. REPRESENTATIONS AND WARRANTIES. (a) Representations and Warranties by Company. The Company represents and warrants to each Underwriter as of the date hereof, the Applicable Time and the Closing Time (as defined below), and agrees with each Underwriter as follows: (i) compliance with the Registration Statement, Prospectus and Incorporation Documents . The Company meets the requirements for use of Form S-3 under the Securities Act. The Registration Statement is an automatic shelf registration statement under Rule 405 and the Notes are and remain eligible for registration by the Company in such automatic shelf registration statement. Each registration statement and any subsequent effective amendment is effective under the Securities Act. No stop order suspending the effectiveness of the registration statement, or any subsequent effective amendment thereto, has been issued under the Securities Act, the Commission’s notice of objection to the use of the registration statement, or any subsequent effective amendment pursuant to Rule 401(g)(2) of the Securities Act Regulations (“Rule 401(g)( 2)”) has been received by the Company, no order restraining or suspending the use of any preliminary prospectus or prospectus or any amendment or supplement thereto has been obtained and no proceedings for any of those purposes have been instituted or pending or contemplated to the knowledge of the Company. The Company has complied with each request (if any) from the Commission for additional information. In addition, the Indenture is qualified under the Trust Indenture Act of 1939, as amended, and the rules and regulations promulgated thereunder (the “Trust Indenture Act”). Each registration statement and any post-effective amendment thereto comply in all material respects with the requirements of the Securities Act, the Securities Act Regulations and the Trust Indenture Act at the time of its effectiveness with respect to the underwriters pursuant to Rule 430B(f)(2) and on each deemed effective date. Each preliminary prospectus and prospectus and any amendment or supplement thereto shall, at the time each is filed with the Commission, comply in all material respects with the Securities Act, the Securities Act regulations, and